SG Americas Securities
CERE

SG Americas Securities’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

SG Americas Securities’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-29,424
Closed -$1.2M – 3653
2024
Q2 		$1.2M Buy
29,424
+24,591
+509% +$1.02M 0.01% 1223
2024
Q1 		$204K Sell
4,833
-19,654
-80% -$826K ﹤0.01% 1962
2023
Q4 		$1.04M Buy
+24,487
New +$704K 0.01% 1004
2023
Q3 		– Sell
-4,556
Closed -$145K – 3301
2023
Q2 		$145K Sell
4,556
-24,798
-84% -$761K ﹤0.01% 1929
2023
Q1 		$716K Buy
29,354
+14,849
+102% +$436K 0.01% 1425
2022
Q4 		$457K Buy
14,505
+4,271
+42% +$121K 0.01% 1619
2022
Q3 		$289K Sell
10,234
-9,437
-48% -$281K ﹤0.01% 2022
2022
Q2 		$520K Buy
+19,671
New +$559K 0.01% 1924
2022
Q1 		– Sell
-7,913
Closed -$257K – 3558
2021
Q4 		$257K Sell
7,913
-17,155
-68% -$605K ﹤0.01% 2536
2021
Q3 		$740K Sell
25,068
-56,671
-69% -$1.59M ﹤0.01% 2169
2021
Q2 		$2.09M Buy
+81,739
New +$1.17M 0.01% 1093

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

SG Americas Securities's CERE Position: Q3 2024 in Review

SG Americas Securities sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 29,424 shares — an estimated $1.2M sold.

SG Americas Securities first reported a position in CERE in Q2 2021 and held it in 11 quarters. The position peaked at $2.09M in Q2 2021. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • SG Americas Securities reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • SG Americas Securities sold 29,424 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $1.2M.
  • SG Americas Securities first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 11 quarters.
  • SG Americas Securities's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $2.09M in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on SG Americas Securities's 13F filing for Q3 2024, filed 3 Oct 2024.